AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22215709
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of IgG from patients
Trial: 22215709
Drug: Sequential addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential addition of β‐blocker propranolol
Trial: 22215709
Drug: Sequential addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential addition of NO synthase inhibitor N(G)‐nitro‐L‐arginine methyl ester
Trial: 17453366
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise regimen (12-week training including guided aerobic exercise once a week and home exercise sessions twice a week)
Trial: 9739036
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral food supplements for 4 weeks in addition to hospital food
Trial: 3196076
Drug: metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metaproterenol sulfate in aerosolized saline solution
Trial: 10546188
Drug: Artemether (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (3.6 mg/kg on day 1, 1.6 mg/kg for the next 4 days)
Trial: 10546188
Drug: Quinine (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (1.6 mg/kg for the first 4 hours, 8 mg every 8 hours for the next 3 days)
Trial: 8912545
Drug: Negative estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative estrogen receptor (ER) detection by immunohistochemistry (IHC)
Trial: 6120706
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing fomocaine and diphenhydramine
Trial: 31782408
Drug: Oxycodone (Oxy)
RxNorm normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (Oxy)
Trial: 23446109
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 to 40 mg/day)
Trial: 21062669
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral estradiol valerate
Trial: 19608684
Drug: Direct sequencing
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct sequencing alone or in combination with denaturing high-performance liquid chromatography
Trial: 1676117
Drug: Ribavirin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (15 mg/kg daily by mouth, average daily dose 1000 mg)
Trial: 6219690
Drug: 13‐cis‐retinoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐cis‐retinoic acid (0.5 mg/kg b.w.)
Trial: 29757354
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily exercises)
Trial: 22663901
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for psychosis (CBTp)
Trial: 20806117
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg once daily
Trial: 16433247
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (10 nM, 1 M, and 100 M)
Trial: 10389797
Drug: Chilled 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 5 min
Trial: 10389797
Drug: Chilled 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 30 min
Trial: 21038647
Drug: Tongfu Granule
RxNorm normalized name: GINGER 4.5 g in 100 mL TOPICAL LIQUID [Gongfu Head Soup Plant and extract platycypresssolution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongfu Granule (TFG), 1 bag, three times per day, for 7 days via oral intake or gastric infusion
Trial: 21038647
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered in the same manner as TFG
Trial: 16112071
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (6 mg/kg) administered once every 2 weeks for 9-11 doses
Trial: 16112071
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once every 2 weeks for 9-11 doses
Trial: 7750316
Drug: Diltiazem (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.1 mg/kg bolus, continuous infusion at 2 micrograms/kg/min during surgery, and 30 mg nasogastric tube every 8 hours)
Trial: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.3 mg/kg O.D.
Trial: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.3 mg/kg B.I.D.
Trial: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.6 mg/kg O.D.
Trial: 22950654
Drug: AZD7687 (5-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7687 (5-60 mg, oral administration)
Trial: 12699264
Drug: Postoperative medical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative medical therapy (progestins with or without estrogens)
Trial: 12699264
Drug: Various drugs
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drugs used before or after surgery
Trial: 8869864
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg twice daily (high dose)
Trial: 8869864
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg twice daily (low dose)
Trial: 6402342
Drug: Sustained-release buccal
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release buccal nitroglycerin (BNTG)
Trial: 30818032
Drug: Mindfulness-Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Stress Reduction (MBSR) plus Treatment as Usual (TAU)
Trial: 29324303
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (first-line)
Trial: 29324303
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg (first-line)
Trial: 29324303
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (second-line)
Trial: 29324303
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg (second-line)
Trial: 27871510
Drug: Atropine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5 mg IV bolus)
Trial: 21471025
Drug: Fentanyl (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1-2 μg/kg/h intravenously)
Trial: 21471025
Drug: Tramadol (0.1-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (0.1-0.2 mg/kg/h intravenously)
Trial: 18395326
Drug: Once-daily vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily vardenafil 10mg for 12 weeks
Trial: 18395326
Drug: Once-daily vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily vardenafil 10mg for 24 weeks
Trial: 18395326
Drug: Once-daily vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily vardenafil 10mg (12 weeks) vs On-demand vardenafil (24 weeks) after washout
Trial: 14534517
Drug: Morphine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (7.5 mg intravenous infusion over 3 hours)
Trial: 14534517
Drug: Quinidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (800 mg, placebo-controlled)
Trial: 11406740
Drug: Oral enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteric‐coated pamidronate (300 mg daily)
Trial: 11406740
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (3 g daily)
Trial: 31724352
Drug: Needle-knife treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-knife treatment, applied 1 time a week for 8 times, targeting specific anatomical points.
Trial: 31724352
Drug: Hydroxychloroquine sulfate,
RxNorm normalized name: Hydroxychloroquine Sulfate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate, 0.2 g each time, 2 times daily for 4 weeks, total of 2 courses.
Trial: 27521445
Drug: subunit cancer
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subunit cancer vaccine (recMAGE‐A3 protein+AS15)
Trial: 27521445
Drug: subunit cancer
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subunit cancer vaccine (recMAGE‐A3 protein+AS15) with intravesical BCG
Trial: 23729804
Drug: Retreatment using
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment using other agents
Trial: 18989589
Drug: Immediate autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate autologous bone graft combined with secondary dental implant
Trial: 19037084
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg QD
Trial: 28891445
Drug: Anti-dementia drug
RxNorm normalized name: ANTI-DEMENTIA DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-dementia drug treatment
Trial: 26758039
Drug: Pulse methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulse methylprednisolone followed by a 25-month course of oral prednisolone (P group, n = 20)
Trial: 26758039
Drug: Combined with
RxNorm normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined with mizoribine (150 mg/day for 24 months, M + P group, n = 20)
Trial: 25189430
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(‐1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge)
Trial: 17679361
Drug: Melatonin, 5
RxNorm normalized name: Melatonin, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin, 5 mg daily for 6 weeks
Trial: 17679361
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Epigastric Pain Syndrome (before treatment)
Trial: 17679361
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Postprandial Disorders Syndrome (before treatment)
Trial: 10541775
Drug: Repro-Dose morphine
RxNorm normalized name: Vital E- Repro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repro-Dose morphine (RDM) once daily
Trial: 10541775
Drug: MST Continuous
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST Continuous (MST) twice daily
Trial: 2682347
Drug: fenfluramine treatment
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenfluramine treatment
Trial: 27066188
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus casei (4 × 10(8) CFU) with prebiotic Inulin (400 mg)
Trial: 24553574
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ethanol
Trial: 24553574
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol
Trial: 22682276
Drug: Expected standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expected standard practice in malaria diagnosis and treatment
Trial: 21060104
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (starting at 2000 mg/d)
Trial: 21060104
Drug: Azathioprine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (starting at 2 mg/kg/d)
Trial: 15743365
Drug: Dexloxiglumide 200
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexloxiglumide 200 mg t.i.d. for 7 days
Trial: 12038783
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of tinzaparin (175 IU/kg)
Trial: 12038783
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of tinzaparin (75 IU/kg)
Trial: 12038783
Drug: Tinzaparin (weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin (weight-adjusted dosing)
Trial: 2763876
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary calcium intake (1752 mg elemental Ca per day)
Trial: 2763876
Drug: Low dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dietary calcium intake (391 mg elemental Ca per day)
Trial: 2763876
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion (2 mg Ca per kg body weight over 5 minutes)
Trial: 2763876
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium load (500 mg as CaCO3)
Trial: 2763876
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (1500 mg Ca per day as CaCO3)
Trial: 2763876
Drug: Low-Ca diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Ca diet (approximately 400 mg Ca per day)
Trial: 7174
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aerosolized carbuterol
Trial: 7174
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aerosolized isoproterenol
Trial: 30323359
Drug: 8IU intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8IU intranasal oxytocin
Trial: 25156269
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d, every night for ≥6 months)
Trial: 16618008
Drug: Hallucination-focused integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hallucination-focused integrative treatment (HIT)
Trial: 16618008
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (RT)
Trial: 12202967
Drug: Propranolol (Inderal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (Inderal, 40 mg)
Trial: 10702882
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of cilostazol (50 to 200 mg)
Trial: 10702882
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral administration of cilostazol (100 mg every 12 hours)
Trial: 10702882
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of cilostazol (50 to 200 mg) and repeated doses (100 mg every 12 hours)
Trial: 8566601
Drug: Ligation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligation plus sclerotherapy (1 mL 1.5% tetradecyl injected just above each band)
Trial: 1909152
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal glyceryl trinitrate (mean dose 18.2 mg over approximately 16 hours)
Trial: 1909152
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate
Trial: 6688154
Drug: Profile group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile group (computerized drug profiles)
Trial: 31910101
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 70 μg (2800 IU)/day
Trial: 31910101
Drug: Anti-thyroid medication
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thyroid medication (ATD)
Trial: 28368269
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (n=52) received a multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii once a day at a dose of 1.25×10^9 CFU from the time of initiation of enteral feeds till discharge
Trial: 23713294
Drug: Wuhuang Tangkangling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuhuang Tangkangling (decoction daily for 8 weeks)
Trial: 23713294
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg x d(‐1) orally once a day) combined with insulin subcutaneous injection
Trial: 21606263
Drug: Low-dose MDCT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDCT and CT enterography with adaptive statistical iterative reconstruction (ASIR)
Trial: 21606263
Drug: Low-dose MDCT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDCT and CT enterography with ASIR
Trial: 21606263
Drug: Standard-dose 64-MDCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose 64-MDCT and CT enterography with filtered back projection (FBP)
Trial: 15042546
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of L-AGE and H-AGE groups
Trial: 9736563
Drug: Rufloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin 200 mg once daily for days 2 to 7
Trial: 7817333
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment consisting of water and sucrose
Trial: 25903286
Drug: MVMH supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVMH supplement
Trial: 24108248
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine or bupivacaine (5 mL or less)
Trial: 24108248
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine or bupivacaine (10 mL or greater)
Trial: 24108248
Drug: Injection volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection volumes of 2.5 and 5 mL
Trial: 24108248
Drug: Injection volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection volumes greater than or equal to 10 mL
Trial: 24108248
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.5% bupivacaine or ropivacaine
Trial: 11231996
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels calculated over 270 min
Trial: 9562229
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (desmopressin nasal spray)
Trial: 9562229
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (desmopressin nasal spray)
Trial: 961473
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion during fructose infusion
Trial: 961473
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of fructose and amino acids
Trial: 961473
Drug: Fructose infusion
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose infusion without amino acids
Trial: 27254033
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine
Trial: 25100053
Drug: Pill-count data
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill-count data